- Home
- ESPR vs IMMP Comparison
ESPR vs IMMP Comparison
Compare ESPR & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESPR
- IMMP
- Stock Information
- Founded
- ESPR 2008
- IMMP 1987
- Country
- ESPR United States
- IMMP Australia
- Employees
- ESPR N/A
- IMMP N/A
- Industry
- ESPR Biotechnology: Pharmaceutical Preparations
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- ESPR Health Care
- IMMP Health Care
- Exchange
- ESPR Nasdaq
- IMMP Nasdaq
- Market Cap
- ESPR 305.0M
- IMMP 304.0M
- IPO Year
- ESPR 2013
- IMMP N/A
- Fundamental
- Price
- ESPR $1.50
- IMMP $1.78
- Analyst Decision
- ESPR Buy
- IMMP Buy
- Analyst Count
- ESPR 7
- IMMP 2
- Target Price
- ESPR $6.36
- IMMP $8.50
- AVG Volume (30 Days)
- ESPR 3.9M
- IMMP 81.1K
- Earning Date
- ESPR 03-04-2025
- IMMP 03-25-2025
- Dividend Yield
- ESPR N/A
- IMMP N/A
- EPS Growth
- ESPR N/A
- IMMP N/A
- EPS
- ESPR N/A
- IMMP N/A
- Revenue
- ESPR $332,314,000.00
- IMMP $3,019,249.00
- Revenue This Year
- ESPR $5.51
- IMMP N/A
- Revenue Next Year
- ESPR $1.42
- IMMP $20.28
- P/E Ratio
- ESPR N/A
- IMMP N/A
- Revenue Growth
- ESPR 185.66
- IMMP 24.11
- 52 Week Low
- ESPR $1.47
- IMMP $1.65
- 52 Week High
- ESPR $3.94
- IMMP $3.34
- Technical
- Relative Strength Index (RSI)
- ESPR 34.95
- IMMP 41.69
- Support Level
- ESPR $1.47
- IMMP $1.65
- Resistance Level
- ESPR $1.61
- IMMP $1.88
- Average True Range (ATR)
- ESPR 0.13
- IMMP 0.10
- MACD
- ESPR -0.01
- IMMP -0.01
- Stochastic Oscillator
- ESPR 7.69
- IMMP 41.94
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.